CTLA4 Haploinsufficiency (CHAI): A Patient Guide
At a Glance
CTLA4 haploinsufficiency (CHAI) is a genetic immune disorder in which reduced CTLA-4 “braking” can cause both autoimmune attacks on healthy tissues and weakened protection against infections. Care combines specialist monitoring, targeted treatment, and infection support.
CTLA4 haploinsufficiency, often referred to as CHAI (CTLA-4 haploinsufficiency with autoimmune infiltration), is a rare genetic condition that fundamentally changes how the immune system behaves. In a healthy body, the immune system uses a protein called CTLA-4 as a critical set of “brakes.” These brakes ensure that immune cells only activate when there is a genuine threat, such as a virus or bacteria, and then switch off once the threat is gone. For those living with CHAI, one of the two copies of the CTLA4 gene responsible for making this protein is mutated, meaning the body does not have enough “brakes” to maintain control [1][2].
Without these essential controls, the immune system can lead to excessive immune activation. This leads to a complex “dual paradox” where the body is simultaneously overactive and under-protected. The overactive side, known as autoimmunity, occurs when immune cells mistakenly attack the body’s own healthy tissues, potentially affecting the blood, lungs, brain, and digestive system. At the same time, the system may fail to produce enough protective antibodies, leading to immunodeficiency, which makes the body more vulnerable to recurrent and sometimes severe infections [3][4].
Because CHAI can affect so many different parts of the body, it is known as a multi-system condition. This means that care is rarely managed by a single doctor, though not every person has every manifestation or needs every specialist listed. Instead, patients typically work with a multidisciplinary team of specialists—including hematologists, gastroenterologists, and pulmonologists—all coordinated by a clinical immunologist who specializes in inborn errors of immunity. This team works together to monitor organ health and stay ahead of potential complications [5][6].
While a diagnosis of CHAI marks the beginning of a lifelong journey, it also opens the door to targeted management strategies. Modern medicine has developed treatments that can provide a CTLA-4-like blockade to help replace the missing “brake” function, as well as supportive therapies to bolster the body’s defenses against infection. By working closely with a specialized care team and maintaining an individualized monitoring schedule, people living with CHAI can find a path toward balancing their immune system and protecting their long-term health [7][8].
In this guide
6 chapters
Understanding Your Diagnosis: CTLA4 Haploinsufficiency (CHAI)
Learn what CTLA4 haploinsufficiency (CHAI) means, including immune symptoms, genetic inheritance, incomplete penetrance, family testing, and long-term monitoring.
The Biology and Genetics of CTLA4 Haploinsufficiency
Learn how CTLA4 haploinsufficiency affects immune regulation, inheritance, penetrance, and diagnosis, including CTLA-4 expression and transendocytosis tests.
How CHAI Affects Your Body: Multi-System Symptoms
Learn how CTLA4 haploinsufficiency (CHAI) can affect blood, lungs, digestion, and the brain, including symptoms to track and questions to ask your care team.
Managing CHAI: From Targeted Therapy to Curative Options
Learn how CTLA4 haploinsufficiency (CHAI) is treated with IVIG, abatacept, immunosuppressants, and HSCT, including benefits, risks, and monitoring needs.
Long-Term Health: Monitoring, Risks, and Warning Signs
Learn how to monitor CTLA4 haploinsufficiency, including infections, EBV and CMV, cancer risks, organ health, and warning signs requiring urgent care.
Building Your Care Team: Specialists and First Visit Preparation
Learn how to build a CTLA4 haploinsufficiency care team, prepare for your first immunology visit, and organize genetic, imaging, lab, and biopsy records.
Common questions in this guide
What is CTLA4 haploinsufficiency, or CHAI?
Why can CHAI cause both autoimmunity and repeated infections?
Which doctors may be involved in CHAI care?
What treatments may be used for CTLA4 haploinsufficiency?
Does everyone with CHAI have the same symptoms?
Get notified when new evidence is published on Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies.
Gámez-Díaz L, Seidel MG
Frontiers in pediatrics 2021; (9()):662645 doi:10.3389/fped.2021.662645.
PMID: 33996698 - 2
Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.
Hou TZ, Verma N, Wanders J, et al.
Blood 2017; (129(11)):1458-1468 doi:10.1182/blood-2016-10-745174.
PMID: 28159733 - 3
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
Schwab C, Gabrysch A, Olbrich P, et al.
The Journal of allergy and clinical immunology 2018; (142(6)):1932-1946 doi:10.1016/j.jaci.2018.02.055.
PMID: 29729943 - 4
Case Report: The first Mainland Chinese case of CTLA4 c.529dupT haploinsufficiency with a 38-year diagnostic delay.
Gu X, Guo J, Li L, et al.
Frontiers in immunology 2026; (17()):1899668 doi:10.3389/fimmu.2026.1899668.
PMID: 42819059 - 5
Primary Immune Regulatory Disorders (PIRD): Tools for Diagnosis and Disease Activity Assessment to Guide Therapy.
Oved JH, Torgerson TR, Chan AY
The journal of allergy and clinical immunology. In practice 2026; (14(7)):1467-1474 doi:10.1016/j.jaip.2026.05.015.
PMID: 42409454 - 6
Therapeutic options for CTLA-4 insufficiency.
Egg D, Rump IC, Mitsuiki N, et al.
The Journal of allergy and clinical immunology 2022; (149(2)):736-746 doi:10.1016/j.jaci.2021.04.039.
PMID: 34111452 - 7
A systematic review of abatacept and belatacept in immune-mediated diseases.
Krek AM, Arnold DD, Martin AC, Raeber ME
Journal of autoimmunity 2026; (163()):103608 doi:10.1016/j.jaut.2026.103608.
PMID: 42567048 - 8
Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline.
Hanitsch L, Baumann U, Boztug K, et al.
European journal of immunology 2020; (50(10)):1432-1446 doi:10.1002/eji.202048713.
PMID: 32845010
This page provides general information about CTLA4 haploinsufficiency (CHAI) for educational purposes and does not replace medical advice. A clinical immunologist and your care team can interpret your genetic variant, symptoms, and treatment options.